Claims
Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.
The antimetabolite methotrexate, especially low-dose use as an anti-inflammatory agent: its cardiovascular outcomes evidence (notably the CIRT trial), anti-inflammatory mechanism, and safety. Not for high-dose oncologic or rheumatologic methotrexate use unless in a cardiovascular comparison.
Contribute
If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim or a question entirely, propose it below. A proposal is reviewed on its wording; accepted proposals are matched against the graph before they enter it.